Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping of Exosome-Like Vesicles.

Autor: Tatiana Altadill, Irene Campoy, Lucia Lanau, Kirandeep Gill, Marina Rigau, Antonio Gil-Moreno, Jaume Reventos, Stephen Byers, Eva Colas, Amrita K Cheema

Publikováno v: PLoS ONE, Vol 11, Iss 3, p e0151339 (2016)

Identification of sensitive and specific biomarkers with clinical and translational utility will require smart experimental strategies that would augment expanding the breadth and depth of molecular measurements within the constraints of currently av

Externí odkaz: https://doaj.org/article/a2c81774863248fab174d377b1fca42d

MicroRNAs as prognostic markers in ovarian cancer

Autor: Xavier Matias-Guiu, Javier de la Torre, Asunción Pérez-Benavente, Jose Luis Sánchez-Iglesias, Silvia Cabrera, Josep Castellví, Eva Colas, Berta Díaz-Feijoo, Mireia Olivan, Francesc Alameda, Antonio Gil-Moreno, Andreas Doll, Josep M. del Campo, Tatiana Altadill, Jaume Reventós, Marta Llauradó, Lucia Lanau, Blanca Majem, Mark S. Carey, Gema Moreno-Bueno, Marina Rigau

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname

et al.
Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcfd46d2d14bcce3c59a201b0cd77bf0
https://doi.org/10.1016/j.mce.2014.03.006

Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping Of Exosome-like Vesicles

Autor: Irene Campoy, Lucia Lanau, Jaume Reventós, Amrita K. Cheema, Antonio Gil-Moreno, Tatiana Altadill, Eva Colas, Kirandeep Gill, Marina Rigau, Stephen W. Byers

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
PLoS ONE, Vol 11, Iss 3, p e0151339 (2016)
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Abierto de la UdL
Universitad de Lleida
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
PLoS ONE

Identification of sensitive and specific biomarkers with clinical and translational utility will require smart experimental strategies that would augment expanding the breadth and depth of molecular measurements within the constraints of currently av

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9433e55bff0db1f90c5c946cef9b0ac0
http://hdl.handle.net/2445/126873

Abstract 4093: Cadherin 'switch' and ovarian cancer: Studies using in vitro models and patient samples

Autor: Jaume Reventós, Jose Luis Sánchez-Iglesias, Laura Devis, Marina Rigau, Blanca Majem, Asunción Pérez-Benavente, Lara Lapyckyj, Marta Llauradó, Josep Castellví, Marina Rosso, María Florencia Abascal, María José Besso, Antonio Gil-Moreno, María Laura Matos, Mónica H. Vazquez-Levin, Lucia Lanau

Publikováno v: Cancer Research. 75:4093-4093

Ovarian cancer (OC) is the 5th leading cause of cancer deaths in women worldwide due to late symptoms and its diagnosis at advanced stages. Epithelial to mesenchymal transition (EMT) is an important step in cancer invasion/metastasis and downregulati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb6b720b2f70919009d3510f6cadf257
https://doi.org/10.1158/1538-7445.am2015-4093

Abstract A56: Identification of a micro RNA profile to predict response to therapy and improve patient survival in ovarian cancer

Autor: Lucia Lanau, Josep Castellví, Antonio Gil-Moreno, Marta Llauradó, Assumpció Pérez-Benavente, Jordi Xercavins, José-Luis Sánchez-Iglesias, Marina Rigau, Xavier Matias-Guiu, Angel Garcia, Francesc Alameda, Josep-Maria Del Campo, Silvia Cabrera, Tatiana Altadill, J. Reventós, Blanca Majem

Publikováno v: Clinical Cancer Research. 19:A56-A56

Introduction & Objectives: Ovarian cancer (OC) is the leading cause of death among gynecological malignancies in developed countries. The standard treatment is surgery plus platinum-paclitaxel (CP/TX) chemotherapy. Nevertheless, 70% of these patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7dfdd7e4aaa97f6e88528e9485611ed5
https://doi.org/10.1158/1078-0432.ovca13-a56